PMID: 26320477Sep 1, 2015Paper

Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study

Asian Pacific Journal of Cancer Prevention : APJCP
Wasithep Limvorapitak, Thana Khawcharoenporn

Abstract

A 6-year retrospective cohort study was conducted among Thai hematologic malignancy (HM) patients receiving intensive chemotherapy. Of the 145 eligible patients receiving 893 chemotherapy sessions, 46.9% were female, median age was 52 years, and the most common HM diagnosis was diffuse large B-cell lymphoma (46.2%). Febrile neutropenia (FN) occurred in 14.9% of chemotherapy sessions with an incidence of 24.8 per 1,000 chemotherapy cycles per year. Independent factors associated with FN were receiving the first chemotherapy cycle [adjusted hazard ratio (aHR) 4.1], having hemoglobin ≤100 g/L (aHR 3.7) and platelet ≤140,000/μL (aHR 2.7) on chemotherapy day and receiving acute myeloid leukemia regimens (aHR 20.8). Granulocyte colony stimulating factor was significantly associated with reduced rate of FN when given in those receiving CHOP regimen. With the median follow-up time of 16 months, the overall survival time was significantly longer in patients without FN than those with FN (61.7 vs. 20.8 months; p<0.001).

References

Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J KlasterskyJ Talcott
Jul 14, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean Klastersky
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererGary H Lyman
Mar 6, 2008·Journal of the National Comprehensive Cancer Network : JNCCN·Jeffrey CrawfordGary H Lyman
Dec 6, 2008·British Journal of Haematology·Ruth PettengellUNKNOWN Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU)
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Sep 4, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Asif Husain OsmaniBilal Ahmed
Apr 30, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Jarin ChindaprasirtKosin Wirasorn
Oct 22, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Jeffrey CrawfordUNKNOWN National comprehensive cancer network

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Ruth PettengellUlrich Jaeger
Revista Panamericana De Salud Pública = Pan American Journal of Public Health
Leslie Pérez RuizAna M Ramos Cedeño
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Peter GilbarIan McPherson
© 2021 Meta ULC. All rights reserved